Text size :

Pharmaceuticals, Murzi (J&J): “In Italy over 127 active clinical trials and 7,500 patients involved”

ADNKRONOS

November 4, 2026

Rome, 4 Nov. (Adnkronos Health) – “It is important to celebrate 50 years and see all the development our company has had in Italy. But above all, with a view to future reasoning, to think about the next 50 years and understand how our company can help the country’s system and Italian patients find answers to all questions related to care needs. So we reason in terms of research: how much more research can be done in Italy? Already today, Johnson & Johnson has over 127 active studies and 7,500 patients involved. We reason in terms of production and the value brought by an important site like Latina, which produces over 4 billion tablets and exports 97% of its production. But we also reason in terms of access, innovation, and new therapies that can allow patients with conditions still having unmet needs to find answers to their care needs.” This was stated by Jacopo Murzi, CEO of Johnson & Johnson Innovative Medicine Italy, at the event organized in the Latina facilities for the celebrations of the 50th anniversary of pharmaceuticals in Italy.

The CEO then outlined the priorities for the next 50 years in the country. “The most important ones,” he explained, “are related to the time of access to medicines, because patients cannot wait: time is not a neutral variable. Then there is a priority related to the valorization of investments made in an important country like Italy. And finally, perhaps the most important priority, is to allow for governance that also helps companies to better plan and foresee what the salient elements of Italian healthcare will be, in order to foresee further investments in the country.”

Jiji Press

Related

Page TOP